Metraipolis › archive › dc_f74fffe7e27c

Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy — Europe PMC PMID:42343037

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42343037
DOI: 10.1007/s00109-[numero omesso]-5
License (as archived): solo-consultazione
Archived: 2026-10-18T23:19:00.047Z
SHA-256 of the archived text: 60c42e484c29802e84b6f2f3d425e7617c55615a6badb42de021b1cf2e0b1788
Stable URL of this page: https://metraipolis.com/documento/dc_f74fffe7e27c

How to cite

Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy — Europe PMC PMID:42343037 — Europe PMC (en), https://europepmc.org/article/MED/42343037 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f74fffe7e27c (Metraipolis archive dc_f74fffe7e27c, sha256 60c42e484c29802e84b6f2f3d425e7617c55615a6badb42de021b1cf2e0b1788)

BibTeX

@misc{dcf74fffe7e27c,
  title = {Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy — Europe PMC PMID:42343037},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42343037},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f74fffe7e27c; sha256 60c42e484c29802e84b6f2f3d425e7617c55615a6badb42de021b1cf2e0b1788},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42343037. Agents can read the archived copy with the MCP tool read_document.